<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Gene Therapy Slows Huntington's Disease By 75% In Landmark Trial | News That's Not Crap</title>
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    <link href="https://fonts.googleapis.com/css2?family=IBM+Plex+Sans:wght@400;500;600;700&family=Instrument+Serif:ital@0;1&display=swap" rel="stylesheet">
    <style>
        :root {
            --wgac-brown: #a1512e;
            --wgac-green-light: #d7f6a4;
            --wgac-blue: #4368ff;
            --wgac-teal: #2dcb98;
            --wgac-coral: #e85d4c;
            --wgac-yellow: #f0c808;
            --wgac-purple: #7b68ee;
            --wgac-pink: #e84393;
            --cream: #faf9f6;
            --dark: #1a1a1a;
            --gray-100: #f5f4f2;
            --gray-200: #e8e6e3;
            --gray-400: #a09d98;
            --gray-600: #6b6761;
            --font-display: 'Instrument Serif', Georgia, serif;
            --font-body: 'IBM Plex Sans', -apple-system, BlinkMacSystemFont, sans-serif;
        }

        * { margin: 0; padding: 0; box-sizing: border-box; }

        body {
            font-family: var(--font-body);
            background: var(--cream);
            color: var(--dark);
            line-height: 1.6;
            -webkit-font-smoothing: antialiased;
        }

        a { color: inherit; text-decoration: none; }

        /* Header */
        .site-header {
            background: var(--dark);
            padding: 0;
            position: sticky;
            top: 0;
            z-index: 1000;
        }

        .header-top {
            display: flex;
            justify-content: space-between;
            align-items: center;
            padding: 1.25rem 3rem;
            border-bottom: 1px solid rgba(255,255,255,0.1);
        }

        .logo {
            display: flex;
            align-items: stretch;
            font-family: var(--font-body);
            font-size: 1rem;
            font-weight: 800;
            text-decoration: none;
        }

        .logo-left {
            background: white;
            color: var(--dark);
            padding: 0.5rem 0.75rem;
            display: flex;
            align-items: center;
            letter-spacing: 0.5px;
        }

        .logo-right {
            background: var(--wgac-blue);
            color: white;
            padding: 0.5rem 0.75rem;
            display: flex;
            align-items: center;
            letter-spacing: 0.5px;
        }

        .header-date {
            color: var(--gray-400);
            font-size: 0.8rem;
            font-weight: 500;
            letter-spacing: 0.5px;
            text-transform: uppercase;
        }

        /* Navigation */
        .main-nav {
            display: flex;
            justify-content: center;
            gap: 2px;
            padding: 0.75rem 0;
            background: var(--dark);
        }

        .nav-link {
            font-size: 0.7rem;
            font-weight: 700;
            letter-spacing: 0.5px;
            text-transform: uppercase;
            padding: 0.5rem 1rem;
            transition: all 0.15s ease;
            background: rgba(255,255,255,0.1);
            color: white;
        }

        .nav-link:hover {
            background: white;
            color: var(--dark);
        }

        .nav-link.active {
            background: var(--wgac-blue);
            color: white;
        }

        /* Article Hero */
        .article-hero {
            position: relative;
            height: 70vh;
            min-height: 500px;
            max-height: 700px;
            overflow: hidden;
        }

        .article-hero img {
            width: 100%;
            height: 100%;
            object-fit: cover;
        }

        .article-hero-overlay {
            position: absolute;
            inset: 0;
            background: linear-gradient(to top, rgba(0,0,0,0.8) 0%, rgba(0,0,0,0.3) 50%, rgba(0,0,0,0.1) 100%);
        }

        .article-hero-content {
            position: absolute;
            bottom: 0;
            left: 0;
            right: 0;
            padding: 4rem;
            max-width: 900px;
            margin: 0 auto;
            text-align: center;
        }

        .article-tag {
            display: inline-block;
            background: var(--wgac-coral);
            color: white;
            padding: 0.35rem 0.75rem;
            font-weight: 700;
            font-size: 0.65rem;
            text-transform: uppercase;
            letter-spacing: 1px;
            margin-bottom: 1.5rem;
        }

        .article-hero h1 {
            font-family: var(--font-display);
            font-size: clamp(2.5rem, 5vw, 3.5rem);
            font-weight: 400;
            line-height: 1.15;
            color: white;
            margin-bottom: 1.5rem;
        }

        .article-meta {
            color: rgba(255,255,255,0.7);
            font-size: 0.9rem;
        }

        .article-meta span { margin: 0 0.75rem; }

        /* Article Content */
        .article-content {
            max-width: 700px;
            margin: 0 auto;
            padding: 4rem 2rem;
        }

        .article-lead {
            font-size: 1.35rem;
            line-height: 1.7;
            color: var(--dark);
            margin-bottom: 2rem;
            font-weight: 400;
        }

        .article-body p {
            font-size: 1.1rem;
            line-height: 1.8;
            margin-bottom: 1.5rem;
            color: var(--gray-600);
        }

        .article-body h2 {
            font-family: var(--font-display);
            font-size: 1.75rem;
            margin: 3rem 0 1.5rem;
            color: var(--dark);
        }

        .article-body blockquote {
            border-left: 3px solid var(--wgac-teal);
            padding-left: 1.5rem;
            margin: 2rem 0;
            font-family: var(--font-display);
            font-size: 1.4rem;
            font-style: italic;
            color: var(--dark);
        }

        /* Stats Box */
        .stats-box {
            background: var(--wgac-teal);
            color: white;
            padding: 2.5rem;
            margin: 3rem 0;
        }

        .stats-box h3 {
            font-family: var(--font-display);
            font-size: 1.25rem;
            margin-bottom: 1.5rem;
        }

        .stats-grid {
            display: grid;
            grid-template-columns: repeat(3, 1fr);
            gap: 2rem;
        }

        .stat-item { text-align: center; }

        .stat-number {
            font-family: var(--font-display);
            font-size: 3rem;
            line-height: 1;
            margin-bottom: 0.5rem;
        }

        .stat-label {
            font-size: 0.8rem;
            opacity: 0.9;
        }

        /* Image with caption */
        .article-figure {
            margin: 3rem -4rem;
        }

        .article-figure img {
            width: 100%;
            display: block;
        }

        .article-figure figcaption {
            font-size: 0.85rem;
            color: var(--gray-400);
            padding: 1rem 4rem;
            text-align: center;
        }

        .sources-box {
            margin-top: 3rem;
            padding: 2rem;
            background: var(--gray-100);
            border-left: 4px solid var(--wgac-teal);
        }

        .sources-box h3 {
            font-family: var(--font-body);
            font-size: 0.8rem;
            font-weight: 700;
            text-transform: uppercase;
            letter-spacing: 1px;
            color: var(--gray-600);
            margin-bottom: 1rem;
        }

        .sources-box ul {
            list-style: none;
        }

        .sources-box li {
            margin-bottom: 0.5rem;
        }

        .sources-box a {
            color: var(--wgac-teal);
            font-size: 0.9rem;
            text-decoration: none;
            border-bottom: 1px solid transparent;
            transition: border-color 0.2s ease;
        }

        .sources-box a:hover {
            border-bottom-color: var(--wgac-teal);
        }

        /* Related Articles */
        .related-section {
            background: var(--gray-100);
            padding: 4rem 2rem;
            margin-top: 4rem;
        }

        .related-inner {
            max-width: 1200px;
            margin: 0 auto;
        }

        .related-title {
            font-family: var(--font-display);
            font-size: 1.5rem;
            margin-bottom: 2rem;
            padding-bottom: 1rem;
            border-bottom: 2px solid var(--dark);
        }

        .related-grid {
            display: grid;
            grid-template-columns: repeat(3, 1fr);
            gap: 2rem;
        }

        .related-card {
            background: white;
            cursor: pointer;
            transition: background 0.2s ease;
        }

        .related-card:hover { background: var(--cream); }
        .related-card:hover h4 { color: var(--wgac-brown); }

        .related-card img {
            width: 100%;
            height: 180px;
            object-fit: cover;
            display: block;
        }

        .related-card-content {
            padding: 1.25rem;
        }

        .related-card h4 {
            font-family: var(--font-display);
            font-size: 1.1rem;
            line-height: 1.35;
            transition: color 0.2s ease;
        }

        /* Footer */
        .site-footer {
            background: var(--dark);
            color: white;
            padding: 4rem 3rem;
        }

        .footer-content {
            max-width: 1400px;
            margin: 0 auto;
            display: flex;
            justify-content: space-between;
            align-items: flex-start;
        }

        .footer-brand {
            max-width: 350px;
        }

        .footer-logo {
            display: flex;
            align-items: stretch;
            font-family: var(--font-body);
            font-size: 0.85rem;
            font-weight: 800;
            margin-bottom: 1rem;
            width: fit-content;
        }

        .footer-logo .logo-left {
            background: white;
            color: var(--dark);
            padding: 0.4rem 0.6rem;
        }

        .footer-logo .logo-right {
            background: var(--wgac-blue);
            color: white;
            padding: 0.4rem 0.6rem;
        }

        .footer-tagline {
            font-size: 0.9rem;
            color: var(--gray-400);
            line-height: 1.6;
        }

        .footer-nav {
            display: flex;
            gap: 4rem;
        }

        .footer-col h4 {
            font-size: 0.7rem;
            font-weight: 700;
            letter-spacing: 1px;
            text-transform: uppercase;
            color: var(--gray-400);
            margin-bottom: 1rem;
        }

        .footer-col ul {
            list-style: none;
        }

        .footer-col li {
            margin-bottom: 0.5rem;
        }

        .footer-col a {
            font-size: 0.9rem;
            color: white;
            opacity: 0.8;
            transition: opacity 0.2s ease;
        }

        .footer-col a:hover {
            opacity: 1;
        }

        .footer-bottom {
            max-width: 1400px;
            margin: 3rem auto 0;
            padding-top: 2rem;
            border-top: 1px solid rgba(255,255,255,0.1);
            font-size: 0.8rem;
            color: var(--gray-400);
            display: flex;
            justify-content: space-between;
            align-items: center;
        }

        .footer-update {
            font-size: 0.7rem;
            opacity: 0.6;
            letter-spacing: 0.5px;
        }

        /* Responsive */
        @media (max-width: 1024px) {
            .related-grid {
                grid-template-columns: 1fr;
            }
            .footer-content {
                flex-direction: column;
                gap: 3rem;
            }
        }

        @media (max-width: 768px) {
            .header-top { padding: 1rem 1.5rem; }
            .main-nav { flex-wrap: wrap; }
            .nav-link { padding: 0.75rem 1rem; font-size: 0.7rem; }
            .article-hero-content { padding: 2rem 1.5rem; }
            .article-content { padding: 2rem 1.5rem; }
            .article-figure { margin: 2rem -1.5rem; }
            .article-figure figcaption { padding: 1rem 1.5rem; }
            .stats-grid { grid-template-columns: 1fr; gap: 1.5rem; }
        }
    </style>
</head>
<body>
    <!-- Header -->
    <header class="site-header">
        <div class="header-top">
            <a href="../index.html" class="logo"><span class="logo-left">NEWS THAT'S NOT</span><span class="logo-right">CRAP</span></a>
            <div class="header-date">Wednesday, January 29, 2026</div>
        </div>
        <nav class="main-nav">
            <a href="../index.html" class="nav-link">Today</a>
            <a href="../climate.html" class="nav-link">Climate</a>
            <a href="../health.html" class="nav-link active">Health</a>
            <a href="../science.html" class="nav-link">Science</a>
            <a href="../people.html" class="nav-link">People</a>
            <a href="../wildlife.html" class="nav-link">Wildlife</a>
            <a href="../cats.html" class="nav-link">Cats</a>
        </nav>
    </header>

    <!-- Article Hero -->
    <div class="article-hero">
        <img src="https://images.unsplash.com/photo-1532094349884-543bc11b234d?w=1920&q=80" alt="Scientists in laboratory">
        <div class="article-hero-overlay"></div>
        <div class="article-hero-content">
            <span class="article-tag">Health</span>
            <h1>AMT-130 Gene Therapy Slows Huntington's Disease By 75% In Landmark Trial</h1>
            <div class="article-meta">
                <span>By Jean Poole</span>
                <span>-</span>
                <span>January 29, 2026</span>
                <span>-</span>
                <span>8 min read</span>
            </div>
        </div>
    </div>

    <!-- Article Content -->
    <article class="article-content">
        <p class="article-lead">
            For the first time in history, a drug has been shown to alter the course of Huntington's disease in clinical trials. UniQure's AMT-130 gene therapy achieved a 75% slowing of disease progression, marking what scientists call "the first domino to fall" in treating this devastating condition.
        </p>

        <div class="article-body">
            <p>
                On September 24, 2025, uniQure announced results that the Huntington's disease community had been waiting decades to hear. Their gene therapy AMT-130, administered through a single surgical procedure, met its primary endpoint with stunning clarity: a statistically significant 75% slowing of disease progression as measured by the composite Unified Huntington's Disease Rating Scale (cUHDRS).
            </p>

            <p>
                Huntington's disease is a cruel genetic lottery. Caused by a mutation in the huntingtin gene, it typically strikes in middle age, progressively destroying the nerve cells in the brain. Patients lose their ability to think, move, and eventually function. Until now, doctors could only offer medications to manage symptoms. Nothing could slow the disease itself.
            </p>

            <blockquote>
                "This is the first time any drug has been shown to alter the course of Huntington's disease in people in a clinical trial. The first domino has fallen."
            </blockquote>

            <p>
                That assessment comes from HDBuzz, a scientific news site run by Huntington's disease researchers. Their cautious optimism reflects years of dashed hopes in this field, but the data from uniQure's Phase I/II trial is unusually robust.
            </p>

            <div class="stats-box">
                <h3>AMT-130 Trial Results (September 2025)</h3>
                <div class="stats-grid">
                    <div class="stat-item">
                        <div class="stat-number">75%</div>
                        <div class="stat-label">Slowing on cUHDRS (p=0.003)</div>
                    </div>
                    <div class="stat-item">
                        <div class="stat-number">60%</div>
                        <div class="stat-label">Slowing on Total Functional Capacity</div>
                    </div>
                    <div class="stat-item">
                        <div class="stat-number">88%</div>
                        <div class="stat-label">Slowing on cognitive tests</div>
                    </div>
                </div>
            </div>

            <h2>How AMT-130 Works</h2>

            <p>
                The therapy uses an adeno-associated virus (AAV) to deliver genetic instructions directly to brain cells. These instructions cause neurons to produce less of the toxic mutant huntingtin protein that drives the disease. Think of it as installing a dimmer switch on the faulty gene.
            </p>

            <p>
                The procedure requires a single neurosurgical operation to inject the therapy into the brain's striatum, the region most affected by Huntington's. It's invasive, but it's a one-time treatment. In the trial, patients who received the high dose showed the most dramatic benefits.
            </p>

            <p>
                According to the company's data, treated patients showed a mean change in cUHDRS from baseline of just -0.38 compared to -1.52 for patients in the external control group. The secondary endpoints were equally encouraging: Total Functional Capacity showed 60% slowing, and the Symbol Digit Modalities Test (a measure of cognitive speed) showed 88% slowing.
            </p>

            <figure class="article-figure">
                <img src="https://images.unsplash.com/photo-1559757175-5700dde675bc?w=1400&q=80" alt="Laboratory research">
                <figcaption>AMT-130 is the first therapeutic candidate to receive FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Huntington's disease. Photo: National Institutes of Health</figcaption>
            </figure>

            <h2>What This Means for Patients</h2>

            <p>
                There are roughly 30,000 people in the United States currently living with Huntington's disease, and another 200,000 who are at risk of developing it because they carry the gene mutation. Globally, the numbers are much larger.
            </p>

            <p>
                The safety profile was also reassuring. As of June 30, 2025, no new drug-related serious adverse events had been observed since December 2022. The most common side effects were related to the surgical procedure itself, and all resolved.
            </p>

            <p>
                UniQure announced in November 2025 that they received positive feedback from the FDA during a pre-Biologics License Application meeting. The company plans to submit a BLA in Q1 2026, with a potential U.S. launch later in the year if approved.
            </p>

            <h2>The Bigger Picture</h2>

            <p>
                Perhaps most importantly, AMT-130's success validates the approach of targeting the underlying genetic cause of neurological diseases. The same technology could potentially be adapted for other conditions like Parkinson's disease, ALS, and certain forms of Alzheimer's.
            </p>

            <p>
                The trial analyzed outcomes for 29 patients treated with AMT-130 (17 high dose, 12 low dose), with 12 patients per dose group having completed 36 months of follow-up. The comparison used a propensity score-matched external control drawn from the Enroll-HD natural history dataset.
            </p>

            <p>
                For families who have watched this disease claim generation after generation, the results represent something they've rarely allowed themselves to feel: genuine hope.
            </p>

            <div class="sources-box">
                <h3>Sources</h3>
                <ul>
                    <li><a href="https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-positive-topline-results-pivotal-phase-iii" target="_blank">uniQure: Positive Topline Results from Pivotal Phase I/II Study</a></li>
                    <li><a href="https://en.hdbuzz.net/the-first-domino-falls-amt-130-gene-therapy-slows-huntingtons-in-landmark-trial/" target="_blank">HDBuzz: The First Domino Falls - AMT-130 Gene Therapy</a></li>
                    <li><a href="https://eurohuntington.org/2025/10/10/recent-results-for-amt-130-a-step-towards-treatments-that-could-slow-huntingtons-disease/" target="_blank">European Huntington Association: Recent Results for AMT-130</a></li>
                    <li><a href="https://www.science.org/content/article/first-gene-therapy-seems-slow-huntington-disease" target="_blank">Science: In a First, a Gene Therapy Seems to Slow Huntington Disease</a></li>
                </ul>
            </div>
        </div>
    </article>

    <!-- Related Articles -->
    <section class="related-section">
        <div class="related-inner">
            <h2 class="related-title">More Health Stories</h2>
            <div class="related-grid">
                <a href="blindness-treatment.html" class="related-card">
                    <img src="https://images.unsplash.com/photo-1579684385127-1ef15d508118?w=600&q=80" alt="Medical research">
                    <div class="related-card-content">
                        <h4>Gene Therapy Gives Blind Children Sight For the First Time</h4>
                    </div>
                </a>
                <a href="mrna-cancer.html" class="related-card">
                    <img src="https://images.unsplash.com/photo-1631549916768-4119b2e5f926?w=600&q=80" alt="Cancer research">
                    <div class="related-card-content">
                        <h4>mRNA Cancer Vaccines Show Promise Against Pancreatic and Melanoma</h4>
                    </div>
                </a>
                <a href="crispr-baby.html" class="related-card">
                    <img src="https://images.unsplash.com/photo-1530026405186-ed1f139313f8?w=600&q=80" alt="Baby">
                    <div class="related-card-content">
                        <h4>Baby KJ: First Personalized CRISPR Therapy Success</h4>
                    </div>
                </a>
            </div>
        </div>
    </section>

    <!-- Footer -->
    <footer class="site-footer">
        <div class="footer-content">
            <div class="footer-brand">
                <div class="footer-logo"><span class="logo-left">NEWS THAT'S NOT</span><span class="logo-right">CRAP</span></div>
                <p class="footer-tagline">Doom-scrolling is so last decade. We bring you the breakthroughs, the victories, and the genuinely good stuff happening in the world.</p>
            </div>
            <nav class="footer-nav">
                <div class="footer-col">
                    <h4>Sections</h4>
                    <ul>
                        <li><a href="../climate.html">Climate</a></li>
                        <li><a href="../health.html">Health</a></li>
                        <li><a href="../science.html">Science</a></li>
                        <li><a href="../people.html">People</a></li>
                        <li><a href="../wildlife.html">Wildlife</a></li>
                        <li><a href="../cats.html">Cats</a></li>
                    </ul>
                </div>
                <div class="footer-col">
                    <h4>About</h4>
                    <ul>
                        <li><a href="../mission.html">Our Mission</a></li>
                        <li><a href="../team.html">Team</a></li>
                        <li><a href="../contact.html">Contact</a></li>
                    </ul>
                </div>
            </nav>
        </div>
        <div class="footer-bottom">
            <span>2026 News That's Not Crap. All the good vibes reserved.</span>
            <span class="footer-update">Updated daily at 6am Eastern</span>
        </div>
    </footer>
</body>
</html>
